l Helu Cas: 171596-29-5 Ke Kumu Molekula: C₂₂H₁₉N₃O₄
| Lae hehee | >193°C |
| ʻO ka mānoanoa | DMF: 25 mg/ml DMF:PBS (pH 7.2) (1:1): 0.5 mg/ml DMSO: 20 mg/ml |
| ka mahana mālama | -20°C |
| hikiwawe | DMF: 25 mg/ml DMF:PBS (pH 7.2) (1:1): 0.5 mg/ml DMSO: 20 mg/ml |
| hana ʻōpika | [α]/D +68 a i +78°, c = 1 i loko o ka chloroform-d |
| Ka nana aku | Paʻa keʻokeʻo i ke keʻokeʻo |
| Maemae | ≥98% |
(inoa mākeke a i ʻole) he ʻano o ka PDE5 inhibitor i hoʻohana ʻia no ka mālama ʻana i ka erectile dysfunction, benign prostatic hypertrophy a me pulmonary arterial hypertension.ʻO ka hopena o ka hoʻomaha ʻana i nā ʻiʻo o nā kīʻaha koko a hoʻonui i ke kahe o ke koko i loko o ka corpus cavernosum.ʻO ke ʻano o ka hana ma o ke kāohi ʻana i ka hana o ka cGMP specific phosphodiesterase type 5 (PDE5).Hoʻohaʻahaʻa ʻo PDE5 i ka cGMP i loko o ka corpus cavernosum a puni ka penis.No laila, ke alakaʻi nei ka tadalafi i ka hoʻonui ʻana o ka cGMP e hoʻonui ai i ka hoʻomaha ʻana o ka ʻiʻo maʻemaʻe a hoʻonui i ke kahe o ke koko i loko o ka corpus cavernosum.Ua hōʻike pū kekahi mau noiʻi lāʻau lapaʻau e hiki ke hoʻomaikaʻi i ka hana endothelia i nā kāne me ka piʻi ʻana o ka maʻi cardiovascular a hoʻohaʻahaʻa i nā hōʻailona urinary tract lua i ka benign prostatic hyperplasia.
analgesic, uptake blocker, mu-opiod receptor agonist.He mea hoʻopaneʻe phosphodiesterase 5.hoʻohana ʻia no ka mālama ʻana i ka erectile dysfunction.
ʻokoʻa ke ʻano mai ka sildenafil a me ka vardenafil.Hoʻopili koke ʻia a piʻi i ka ʻike (378 μg/L ma hope o kahi 20-mg dose) ma hope o 2 mau hola, e hōʻike ana i ka hapalua o ke ola o 17.5 mau hola.Hoʻopili ʻia ia e ke ake (CYP3A4).ʻO ka mea nui, ʻaʻole i hoʻopili ʻia kāna pharmacokinetics e ka waiʻona a i ʻole ka ʻai ʻana i ka meaʻai a i ʻole nā mea e like me ka maʻi maʻi a i ʻole ka hana hepatic a i ʻole ka hana renal.
